Prestige Consumer Healthcare (PBH) Projected to Post Quarterly Earnings on Thursday

Key Points

• Prestige Consumer Healthcare is expected to report Q2 fiscal 2027 results before market open on November 5, 2026. Analysts forecast earnings of $1.07 per share on $329.15 million in revenue, while the company’s full-year EPS guidance is $4.55–$4.65.
• The company exceeded expectations in its latest quarter, reporting $0.98 EPS versus the $0.89 consensus estimate and $265.71 million in revenue. Revenue increased 6.5% year over year.
• PBH shares opened at $47.81, well below their 12-month high of $71.07. Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $67.67.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) is projected to announce its Q2 2027 results before the market opens on Thursday, November 5th. Analysts expect Prestige Consumer Healthcare to post earnings of $1.07 per share and revenue of $329.15 million for the quarter. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Parties are encouraged to explore the company's upcoming Q2 2027 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.09. The firm had revenue of $265.71 million during the quarter, compared to analysts' expectations of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The firm's quarterly revenue was up 6.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.90 earnings per share. On average, analysts expect Prestige Consumer Healthcare to post $4.56 EPS for the current fiscal year and $5.09 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Up 0.9%

Shares of Prestige Consumer Healthcare stock opened at $47.81 on Thursday. The company has a market cap of $2.26 billion, a price-to-earnings ratio of 13.39, a price-to-earnings-growth ratio of 1.50 and a beta of 0.34. The company's 50 day moving average is $48.63 and its 200 day moving average is $54.36. Prestige Consumer Healthcare has a twelve month low of $42.62 and a twelve month high of $71.07. The company has a quick ratio of 1.99, a current ratio of 3.23 and a debt-to-equity ratio of 1.06.

Analysts Set New Price Targets

A number of research firms have commented on PBH. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. Zacks Research raised Prestige Consumer Healthcare from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $67.67.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc NYSE: PBH is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company's brands include Dramamine and Bonine for motion-sickness relief; BC and Goody's for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer's Eve for feminine care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.